Articles

Poll

Podcasts

Slideshows

Videos

Rheumatology

Rheumatology condition center page is a comprehensive resource for clinical news and insights on rheumatologic disease. This page consists of interviews, articles, podcasts, and videos on the research, treatment and development of therapies for arthritis, gout, nr-AxSpA, and more.

Investigators found an incidence of 26.2 severe infections per 100 patient-years with 4 deaths in the study.

High Risk of Severe Infections in Patients With Rheumatic Diseases After Kidney Transplant

Small molecule drugs may help fill gaps in treatment with biologic therapies.

Meta-Analysis Confirms Efficacy of Small Molecules for Psoriatic Arthritis

A recent study identified the prevalence of asymptomatic pulmonary involvement in patients with newly diagnosed RA or PsA, highlighting the need to reevaluate screening protocols.

Nearly 65% of Patients with RA, PsA Had Asymptomatic Pulmonary Involvement

Cell therapy, particularly CAR-T, is expanding into autoimmune diseases like lupus and multiple sclerosis. While promising, safety, efficacy, and broad applicability remain uncertain.

Leveling Up: Cell Therapy Research Expands Horizons in Autoimmune Disease

After 16 weeks of treatment, a significantly greater proportion of deucravacitinib-treated patients achieved ACR20 response.

Deucravacitinib Meets ACR20 Endpoint for Psoriatic Arthritis in Phase 3 Trial

The COSMOS trial showed guselkumab every 8 weeks improved PsA outcomes through week 48, including in patients with inadequate responses to TNF inhibitors.

Guselkumab 100 mg Every 8 Weeks Consistently Improves Joint, Skin Through Week 24

A prospective study also found that the presence of psoriasis and dactylitis at disease onset were the strongest predictors for the development of PsA. 

CASPAR Criteria May Identify More Patients With Juvenile PsA Than ILAR Criteria 

Ustekinumab-kfce is planned for launch in February 2025 according to a previous settlement and license agreement with Janssen.

FDA Approves Ustekinumab (STELARA) Biosimilar for Crohn’s, UC, Psoriasis, PsA

Findings from PsABIOnd can help reassure clinicians of similar efficacy between treatment choices. 

Real-World Study Confirms Similar Efficacy of Guselkumab and IL-17i for PsA

The findings are especially important as differences in disease characteristics and outcomes between male and female patients become more clear. 

Guselkumab Similarly Efficacious Among Male, Female Patients With PsA 

On the HCPLive psoriatic arthritis page, resources on the topics of medical news and expert insight into PsA can be found. Content includes articles, interviews, videos, podcasts, and breaking news on arthritis, and more.